VictORION-INCLUSION: Evaluating INClisiran as a soLUtion to Improve LDL-C Management and cloSe Care Gaps in an Inclusive ASCVD and ASCVD Risk Equivalent populatiON
Latest Information Update: 23 Feb 2025
Price :
$35 *
At a glance
- Drugs Inclisiran (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms VictORION-INCLUSION
- Sponsors Novartis Pharmaceuticals
- 24 Jan 2025 Planned End Date changed from 1 Jul 2026 to 1 Aug 2027.
- 24 Jan 2025 Planned primary completion date changed from 1 Nov 2026 to 1 Aug 2026.
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.